Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial.

Ikegami, Yuichi; Takenaka, Yasuhiro; Saito, Daigo; Shimada, Akira; Inoue, Ikuo

Ikegami, Yuichi; Takenaka, Yasuhiro; Saito, Daigo; Shimada, Akira; Inoue, Ikuo.

Afiliación

Ikegami Y; Department of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan.
Takenaka Y; These authors contributed equally to this work.
Saito D; Department of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan.
Shimada A; Department of Physiology, Graduate School of Medicine, Nippon Medical School, 1-25-16 Nezu, Bunkyo, Tokyo 113-0031, Japan.
Inoue I; These authors contributed equally to this work.

J Clin Med Res ; 13(10-11): 502-509, 2021 Nov.

Article en En | MEDLINE | ID: mdl-34925661

Palabras clave

Anagliptin; Dipeptidyl peptidase-4 inhibitor; Glucagon-like peptide-1; Lathosterol; Low-density lipoprotein cholesterol

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Res Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Canadá

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google